Effects of <scp> <i>CYP2C19</i> </scp> genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy-Reference-Cited by-同舟云学术

Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy

Published:2022-08-30 Issue:11 Volume:63 Page:2958-2969
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Ahn Seon‐Jae¹²^ORCID,Oh Jaeseong³,Kim Do‐Yong¹^ORCID,Son Hyoshin²⁴,Hwang Sungeun⁵,Shin Hye‐Rim⁶,Kim Eun Young⁷,Lee Han Sang¹²,Lee Woo‐Jin¹⁸,Moon Jangsup¹⁹^ORCID,Lee Soon‐Tae¹,Jung Keun‐Hwa¹,Park Kyung‐Il¹¹⁰^ORCID,Jung Ki‐Young¹,Lee SeungHwan³,Yu Kyung‐Sang³,Chu Kon¹^ORCID,Lee Sang Kun¹^ORCID

Affiliation:

1. Department of Neurology Seoul National University Hospital, Seoul National University College of Medicine Seoul South Korea

2. Hospital Medicine Center Seoul National University Hospital Seoul South Korea

3. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul South Korea

4. Department of Neurosurgery Seoul National University Hospital Seoul South Korea

5. Department of Neurology Ewha Womans University Mokdong Hospital Seoul South Korea

6. Department of Neurology Dankook University Hospital Cheonan South Korea

7. Department of Neurology Chungnam National University Sejong Hospital Sejong South Korea

8. Department of Neurology Seoul National University Bundang Hospital Seongnam‐si South Korea

9. Department of Genomic Medicine Seoul National University Hospital Seoul South Korea

10. Department of Neurology Seoul National University Hospital Healthcare System Gangnam Center Seoul South Korea

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.17399

Reference24 articles.

1. Lacosamide

2. Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial-Onset Seizures

3. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial

4. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lacosamide

5. Pharma. U.Vimpat® (lacaosmide): EMA summary of product characteristics.https://wwwemaeuropaeu/en/documents/product‐information/vimpat‐epar‐product‐information_enpdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic polymorphisms of drug-metabolizing enzymes in older and newer anti-seizure medications;Expert Opinion on Drug Metabolism & Toxicology;2024-05-31

2. How to handle a missed or delayed dose of lacosamide in pediatric patients with epilepsy? a mode-informed individual dosing;Epilepsy & Behavior;2024-02

3. Development of a UPLC-MS/MS method for the determination of lacosamide and its metabolite and its application to drug-drug interaction;Frontiers in Pharmacology;2023-11-10

4. Lacosamide;Reactions Weekly;2023-07-01

5. A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy;Epilepsia Open;2023-05-15